Biomarker Partnering Terms and Agreements
Current Partnering
February 1, 2012 594 Pages - SKU: WWV6778084
|
|
The Biomarker Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the biomarker partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter biomarker partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors biomarker technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.
This report contains over 1000 links to online copies of actual biomarker deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.
The initial chapters of this report provide an orientation of biomarker dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in biomarker dealmaking since 2007, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading biomarker deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of biomarker deals as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of biomarker partnering deals signed and announced since 2007, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in biomarker partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of biomarker technologies and products.
Biomarker Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to biomarker trends and structure of deals entered into by leading companies worldwide.
Biomarker Partnering Terms and Agreements includes:
- Trends in biomarker dealmaking in the biopharma industry since 2075
- Analysis of biomarker deal structure
- Access to headline, upfront, milestone and royalty data
- Case studies of real-life biomarker deals
- Access to over 1000 biomarker contract documents
- The leading biomarker deals by value since 2007
- Most active biomarker dealmakers since 2007
- The leading biomarker partnering resources
In Biomarker Partnering Terms and Agreements, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Biomarker Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 550 biomarker deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise biomarker rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
|
- Executive Summary
- Chapter 1 - Introduction
- Chapter 2 - Trends in biomarker dealmaking
- 2.1. Introduction
- 2.2. Biomarker partnering over the years
- 2.3. Bigpharma biomarker dealmaking activity
- 2.4. Bigpharma not active in biomarkers
- 2.5. Biomarker partnering by deal type
- 2.6. Biomarker partnering by disease type
- 2.7 Average deal terms for biomarkers
- 2.7.1 Biomarker headline values
- 2.7.2 Biomarker upfront payments
- 2.7.3 Biomarker milestone payments
- 2.7.4 Biomarker royalty rates
- Chapter 3 - Leading biomarker deals
- 3.1. Introduction
- 3.2. Top biomarker deals by value
- 3.3. Top biomarker deals involving bigpharma
- Chapter 4 - Bigpharma biomarker deals
- 4.1. Introduction
- 4.2. How to use bigpharma biomarker partnering deals
- 4.3. Bigpharma biomarker partnering company profiles
- Abbott
- Actavis
- Alcon Labs
- Allergan
- Amgen
- Apotex
- Astellas
- AstraZeneca
- Baxter International
- Bayer
- Bayer Healthcare
- Bayer Schering Pharma
- Bayer Vital
- Biogen Idec
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Celgene
- Cephalon
- Chugai
- CSL
- Daiichi Sankyo
- Dainippon Sumitomo
- Eisai
- Eli Lilly
- Forest Laboratories
- Genzyme
- Genzyme Genetics
- Gilead Sciences
- GlaxoSmithKline
- Hospira
- Johnson & Johnson
- Janssen Pharmaceutica NV
- Kyowa Hakko Kirin
- Lundbeck
- Menarini
- Merck & Co
- Merck Sharpe & Dohme
- Merck KGaA
- Merck KGaA
- Merck Serono
- Mitsubishi Tanabe
- Mylan
- Novartis
- Novartis Molecular Diagnostics
- Novo Nordisk
- Nycomed Pharma
- Otsuka
- Pfizer
- Roche
- Roche Applied Science
- Roche Diagnostics
- Roche Molecular Systems
- Roche NimbleGen
- Genentech
- Sanofi
- Servier
- Shionogi
- Shire
- Stada
- Takeda
- Teva
- UCB
- Warner Chilcott
- Watson
- Chapter 5 - Biomarker dealmaking directory
- 5.1. Introduction
- 5.2. Company A-Z
- 5.3. By stage of development
- Discovery
- Preclinical
- Phase I
- Phase II
- Phase III
- Regulatory
- Marketed
- 5.4. By deal type
- Asset purchase
- Bigpharma outlicensing
- Co-development
- Collaborative R&D
- Co-market
- Contract service
- Co-promotion
- CRADA
- Cross-licensing
- Development
- Distribution
- Equity purchase
- Evaluation
- Grant
- Joint venture
- Licensing
- Manufacturing
- Manufacturing - OEM
- Marketing
- Option
- Promotion
- Research
- Settlement
- Spin out
- Sub-license
- Supply
- Termination
- 5.5. By therapy area
- Cardiovascular
- Central Nervous System
- Dental
- Dermatology
- Gastrointestinal
- Genetic disorders
- Genitourinary
- Hematology
- Hospital care
- Immunology
- Infectives
- Inflammatory
- Metabolic
- Musculoskeletal
- Oncology
- Respiratory
- Chapter 6 - Biomarker partnering resource center
- 6.1. Online biomarker partnering
- 6.2. Biomarker partnering events
- 6.3. Further reading on biomarker dealmaking
- Appendices
- Appendix 1 - Deal type definitions
- Appendix 2 - Example biomarker partnering agreement
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Recent titles from CurrentPartnering
- Order Form - Reports
- Table of figures
- Figure 1: Biomarker partnering since 2007
- Figure 2: Bigpharma - top 50 - biomarker deals 2007 to 2011
- Figure 3: Bigpharma diagnostic deal frequency - 2007 to 2011
- Figure 4: Inactive bigpharma in biomarkers 2007-2011
- Figure 5: Biomarker partnering by deal type since 2007
- Figure 6: Biomarker partnering by disease type since 2007
- Figure 7: Biomarker partnering by oncology target since 2007
- Figure 8: Biomarker deals with a headline value
- Figure 9: Biomarker deal headline value distribution, US$million - 2007-2011 - Discovery stage
- Figure 10: Biomarker deal headline value distribution, US$million - 2007-2011 - Discovery stage - detail
- Figure 11: Biomarker deals with upfront payment values
- Figure 12: Biomarker deals with milestone payments
- Figure 13: Biomarker deals with royalty rates, %
- Figure 14: Top biomarker deals by value since 2007
- Figure 15: Top biomarker deals signed by bigpharma value since 2007
- Figure 16: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Cardiovascular)
- Figure 17: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Central Nervous System)
- Figure 18: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dental)
- Figure 19: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Dermatology)
- Figure 20: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Gastrointestinal)
- Figure 21: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Genetic disorders)
- Figure 22: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Genitourinary)
- Figure 23: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hematology)
- Figure 24: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Hospital care)
- Figure 25: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Immunology)
- Figure 26: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Infectives)
- Figure 27: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Inflammatory)
- Figure 28: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Metabolic)
- Figure 29: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Musculoskeletal)
- Figure 30: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Oncology)
- Figure 31: Recent deals (Jan 2007 to Dec 2011) - By therapy area (Respiratory)
- Figure 32: Online partnering resources
- Figure 33: Forthcoming partnering events
- Figure 34: Deal type definitions
- Figure 35: Biomarker partnering agreement between GlaxoSmithKline and Response Genetics, May 2010
Share this report
Other tasks Related Markets Biomarkers Reports Free Alert Me service Receive bi-weekly email alerts on new market research Sign Up Today!
|
